Maxwell Biotech Group consists of three major parts:

Sources of capital

Maxwell Biotech Venture Fund is the first Russian venture fund fully dedicated to investments in the life sciences sector. Maxwell Biotech Venture Fund is managed by one of the leading Russian financial firms, Maxwell Asset Management, that has engaged a team of professionals with decades of experience in healthcare, biotechnology and investment banking industry.

Portfolio companies

Maxwell Biotech Group is investing in product development companies
specializing in specific therapeutic areas or medical devices.

MBG has 7 biotech companies in its portfolio, with 9 innovative
clinical stage drug candidates in development:

Hepatera (liver diseases), NeuroMax (CNS diseases), Infectex
(infectious diseases), Eleventa (asthma, allergies and respiratory
diseases), Osteros Biomedica (bone cancer), OncoMax (oncology
diseases), Photonics (laser systems for surgery of soft and hard
tissues).

Support groups

MBG Clinical Operations group manages clinical trials on Russian territory leveraging a huge resource of Russian clinical centers and physicians that have over the years conducted hundreds of studies sponsored by global biopharma companies and produced results fully compliant with FDA and EMEA standards. MBG Analytics is a group of analysts that evaluates market potential of products, provides competition analysis in various therapeutic areas and assists startups with preparing business plans. MBG Expert Network includes numerous experts and advisors, both in Russia and in the US and Europe, in a variety of disease areas, as well as legal, IP and regulatory advisors.MBG seeks companies with innovative products all over the world and invests in them through financing and conducting clinical trials. In addition to making investments on its own, MBG is actively pursuing joint investment opportunities with many venture funds in North America, Europe, Israel, Australia and other parts of the world.

Maxwell Biotech Group key investment sources:

• Network of relationships with Western biotechnology companies actively developed through our management and advisors
• Numerous sources of innovation in scientific institutes and private companies based on decades of research and development experience
• Readily available human capital, including excellent scientists and entrepreneurs